Overview

Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Status:
Unknown status

Trial end date:
2017-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare safety and efficacy of stem cell mobilization using G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in Hodgkin's lymphoma and non-Hodgkin's lymphoma patients.

Phase:

Phase 3

Details

Lead Sponsor:

Maria Sklodowska-Curie Institute - Oncology Center
Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology

Treatments:

Cytarabine
Lenograstim